Cohance Swaps Vials for Value—Sells CR Bio Unit for ₹160 Cr

Unknown Apr 02, 2026 1,650 Views

Cohance Lifesciences Ltd. (COHA.NS) today announced the sale of its Clinical Research and Bio-Analytical Studies (CR Bio) segment for aggregate consideration of ₹160 crore, as part of its strategic portfolio re-balancing initiative. The transaction is expected to close during the second quarter o...